将新型儿童疫苗纳入中国国家免疫规划:证据、效益与优先级
中国国家免疫规划未包含肺炎球菌结合疫苗(PCV)、轮状病毒疫苗、b型流感嗜血杆菌(Hib)疫苗和水痘疫苗等私立市场可及的疫苗。该综述评估这四种疫苗的疾病负担、覆盖率、不平等性和成本效果,并基于多准则决策分析提出纳入国家免疫规划的优先级顺序:PCV13、轮状病毒疫苗、Hib疫苗、水痘疫苗。
要点
- 2019年将四种非规划疫苗纳入国家免疫规划可避免11761例5岁以下儿童死亡,占5岁以下儿童总死亡的10.29%。
- PCV13覆盖率最低且最不公平,但可预防死亡数最高。
- 多准则决策分析建议的优先顺序为PCV13、轮状病毒疫苗、Hib疫苗、水痘疫苗。
核心结论
- 将PCV13、轮状病毒疫苗、Hib疫苗和水痘疫苗纳入中国国家免疫规划可产生显著健康效益,多准则决策分析建议的优先顺序为PCV13、轮状病毒疫苗、Hib疫苗、水痘疫苗。
研究设计与样本
- 文献综述,评估中国四种非国家免疫规划疫苗的疾病负担、覆盖率、不平等性和成本效果,并进行预算分析和多准则决策分析。
主要发现
- 基于现有证据计算,2019年将四种疫苗纳入国家免疫规划可避免11761例5岁以下儿童死亡,占5岁以下儿童总死亡的10.29%,死亡率从7.8/1000降至7.0/1000。
- PCV13覆盖率最低且最不公平,但可预防的死亡数最高。
关键数值与推荐
- 多准则决策分析建议的优先顺序:PCV13、轮状病毒疫苗、Hib疫苗、水痘疫苗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
China's National Immunization Program has made remarkable achievements but does not include several important childhood vaccines that are readily available in the private market, such as pneumococcal conjugate vaccine (PCV), rotavirus vaccine, Haemophilus influenzae serotype b (Hib) vaccine, and varicella vaccine. We reviewed the literature to assess these four non-National Immunization Program vaccines in terms of their disease burdens, coverage, inequalities, and cost-effectiveness in China and aimed to recommend priorities for introducing them to the National Immunization Program. Based on our calculations using the available evidence, incorporating these vaccines into China's National Immunization Program in 2019 could have averted 11 761 deaths among children younger than 5 years, accounting for 10·29% of the total deaths in children younger than 5 years and reducing the mortality rate from 7·8 per 1000 to 7·0 per 1000. The review showed that 13-valent PCV (PCV13) had the lowest and most inequitable coverage but could prevent the highest number of deaths. In a budgetary analysis for the cohort of newborns in 2023, we estimated that the projected aggregate government costs were US$1954·92 million for PCV13, $1273·13 million for pentavalent rotavirus vaccine, $415·30 million for Hib vaccine, and $221·64 million for varicella vaccine. Our overall multicriteria decision analysis suggested the following priority order for introducing these four non-programme vaccines to the National Immunization Program to benefit the Chinese population: PCV13, rotavirus vaccine, Hib vaccine, and varicella vaccine.
引用
- Zhang H, Lai X, Patenaude BN, et al. Adding new childhood vaccines to China's National Immunization Program: evidence, benefits, and priorities. Lancet Public Health. 2023. PMID: 38000881. doi:10.1016/S2468-2667(23)00248-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。